Trade names Trusopt MedlinePlus a602022 ATC code S01EC03 (WHO) CAS ID 130693-82-2 | AHFS/Drugs.com Monograph Routes of
administration Topical (eye drops) Molar mass 324.443 g/mol | |
 | ||
Pregnancy
category US: C (Risk not ruled out) | ||
Dorzolamide (trade name Trusopt) is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour. It is administered as a topical ophthalmic in the form of a 2% solution.
Contents
Dorzolamide drug pharmacology overview
History
This drug, developed by Merck, was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design. It was developed to circumvent the systemic side effects of acetazolamide which has to be taken orally.
Uses
Dorzolamide hydrochloride is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.
Pharmacodynamics
It lowers IOP by about 20%.
Side effects
Ocular stinging, burning, itching and bitter taste. It causes shallowing of the anterior chamber and leads to transient myopia.
References
Dorzolamide Wikipedia(Text) CC BY-SA